Annexon launches Phase 1b study of ANX-005 in combination with IVIG in subjects with Guillain-Barré syndrome
Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the immune system attacks the peripheral nervous system.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more